L&G Pharma Breakthrough ETF
Werbung
L&G Pharma Breakthrough ETF Kurs - 1 Jahr
Baader Bank Berlin gettex BX World Düsseldorf Lang & Schwarz London München Stuttgart SIX SX USD Tradegate XETRA Quotrix| Emittent | LGIM Managers |
| Auflagedatum | 18.01.2018 |
| Kategorie | Aktien |
| Fondswährung | USD |
| Benchmark | Solactive Pharma Breakthrough V NR USD |
| Ausschüttungsart | Thesaurierend |
| Total Expense Ratio (TER) | 0,49 % |
| Fondsgröße | 15.522.808,61 |
| Replikationsart | Physisch vollständig |
| Morningstar Rating |
Anlageziel L&G Pharma Breakthrough UCITS ETF
So investiert der L&G Pharma Breakthrough UCITS ETF: The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Der L&G Pharma Breakthrough UCITS ETF gehört zur Kategorie "Aktien".
Wertentwicklung (NAV) WKN: A2H9XR
| 3 Monate | 6 Monate | 1 Jahr | 3 Jahre | 5 Jahre | 2024 | |
|---|---|---|---|---|---|---|
| Performance | -3,80 % | +13,87 % | +7,80 % | -15,25 % | +1,47 % | +2,69 % |
| Outperformance ggü. Kategorie | -3,24 % | +6,94 % | -16,02 % | -17,32 % | -26,59 % | -4,33 % |
| Max Verlust | - | - | -11,34 % | -28,07 % | -30,10 % | - |
| Kurs | 9,50 $ | 8,48 $ | 8,72 $ | 11,69 $ | - | 10,76 $ |
| Hoch | - | - | 11,20 $ | - | - | - |
| Tief | - | - | 9,01 $ | - | - | - |
Kennzahlen ISIN: IE00BF0H7608
| Name | 1 Jahr | 3 Jahre | 5 Jahre | 10 Jahre |
|---|---|---|---|---|
| Volatilität | 15,24 % | 14,87 % | 17,07 % | |
| Sharpe Ratio | +0,49 | -0,63 | +0,06 |
Zusammensetzung WKN: A2H9XR
Größte Positionen ISIN: IE00BF0H7608
| Name | ISIN | Marktkapitalisierung | Gewichtung |
|---|---|---|---|
| Pharma Mar SA | ES0169501022 | 1.348.050.000 € | 4,66 % |
| Agios Pharmaceuticals Inc | US00847X1046 | 3.167.682.985 € | 3,64 % |
| Xeris Biopharma Holdings Inc | US98422E1038 | 487.007.859 € | 3,38 % |
| Ligand Pharmaceuticals Inc | US53220K5048 | 2.192.623.805 € | 3,28 % |
| Bristol-Myers Squibb Co | US1101221083 | 113.824.448.442 € | 3,22 % |
| InnoCare Pharma Ltd | KYG4783B1032 | 1.221.482.878 € | 3,18 % |
| Jazz Pharmaceuticals PLC | IE00B4Q5ZN47 | 7.020.310.577 € | 3,06 % |
| Nippon Shinyaku Co Ltd | JP3717600005 | 1.816.152.439 € | 3,01 % |
| argenx SE ADR | US04016X1019 | € | 2,99 % |
| Catalyst Pharmaceuticals Inc | US14888U1016 | 2.523.018.654 € | 2,99 % |
| Summe Top 10 | 33,42 % | ||